Literature DB >> 25903348

Particle-to-PFU ratio of Ebola virus influences disease course and survival in cynomolgus macaques.

Kendra J Alfson, Laura E Avena, Michael W Beadles, Hilary Staples, Jerritt W Nunneley, Anysha Ticer, Edward J Dick, Michael A Owston, Christopher Reed, Jean L Patterson, Ricardo Carrion, Anthony Griffiths.   

Abstract

UNLABELLED: This study addresses the role of Ebola virus (EBOV) specific infectivity in virulence. Filoviruses are highly lethal, enveloped, single-stranded negative-sense RNA viruses that can cause hemorrhagic fever. No approved vaccines or therapies exist for filovirus infections, and infectious virus must be handled in maximum containment. Efficacy testing of countermeasures, in addition to investigations of pathogenicity and immune response, often requires a well-characterized animal model. For EBOV, an obstacle in performing accurate disease modeling is a poor understanding of what constitutes an infectious dose in animal models. One well-recognized consequence of viral passage in cell culture is a change in specific infectivity, often measured as a particle-to-PFU ratio. Here, we report that serial passages of EBOV in cell culture resulted in a decrease in particle-to-PFU ratio. Notably, this correlated with decreased potency in a lethal cynomolgus macaque (Macaca fascicularis) model of infection; animals were infected with the same viral dose as determined by plaque assay, but animals that received more virus particles exhibited increased disease. This suggests that some particles are unable to form a plaque in a cell culture assay but are able to result in lethal disease in vivo. These results have a significant impact on how future studies are designed to model EBOV disease and test countermeasures. IMPORTANCE: Ebola virus (EBOV) can cause severe hemorrhagic disease with a high case-fatality rate, and there are no approved vaccines or therapies. Specific infectivity can be considered the total number of viral particles per PFU, and its impact on disease is poorly understood. In stocks of most mammalian viruses, there are particles that are unable to complete an infectious cycle or unable to cause cell pathology in cultured cells. We asked if these particles cause disease in nonhuman primates by infecting monkeys with equal infectious doses of genetically identical stocks possessing either high or low specific infectivities. Interestingly, some particles that did not yield plaques in cell culture assays were able to result in lethal disease in vivo. Furthermore, the number of PFU needed to induce lethal disease in animals was very low. Our results have a significant impact on how future studies are designed to model EBOV disease and test countermeasures.

Entities:  

Mesh:

Year:  2015        PMID: 25903348      PMCID: PMC4468478          DOI: 10.1128/JVI.00649-15

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  32 in total

1.  The ratio of physical particles per infectious unit observed for poliomyelitis viruses.

Authors:  C E SCHWERDT; J FOGH
Journal:  Virology       Date:  1957-08       Impact factor: 3.616

2.  The Identification and Characterization of Bacteriophages with the Electron Microscope.

Authors:  S E Luria; T F Anderson
Journal:  Proc Natl Acad Sci U S A       Date:  1942-04       Impact factor: 11.205

3.  The FDA animal efficacy rule and biodefense.

Authors:  Gigi Kwik Gronvall; Dennis Trent; Luciana Borio; Robert Brey; Lee Nagao
Journal:  Nat Biotechnol       Date:  2007-10       Impact factor: 54.908

4.  Comprehensive panel of real-time TaqMan polymerase chain reaction assays for detection and absolute quantification of filoviruses, arenaviruses, and New World hantaviruses.

Authors:  Adrienne R Trombley; Leslie Wachter; Jeffrey Garrison; Valerie A Buckley-Beason; Jordan Jahrling; Lisa E Hensley; Randal J Schoepp; David A Norwood; Augustine Goba; Joseph N Fair; David A Kulesh
Journal:  Am J Trop Med Hyg       Date:  2010-05       Impact factor: 2.345

Review 5.  Rapid evolution of RNA genomes.

Authors:  J Holland; K Spindler; F Horodyski; E Grabau; S Nichol; S VandePol
Journal:  Science       Date:  1982-03-26       Impact factor: 47.728

6.  Experimental inoculation of plants and animals with Ebola virus.

Authors:  R Swanepoel; P A Leman; F J Burt; N A Zachariades; L E Braack; T G Ksiazek; P E Rollin; S R Zaki; C J Peters
Journal:  Emerg Infect Dis       Date:  1996 Oct-Dec       Impact factor: 6.883

7.  Multiple genetic variants arise in the course of replication of foot-and-mouth disease virus in cell culture.

Authors:  F Sobrino; M Dávila; J Ortín; E Domingo
Journal:  Virology       Date:  1983-07-30       Impact factor: 3.616

Review 8.  Molecular biology of rubella virus.

Authors:  T K Frey
Journal:  Adv Virus Res       Date:  1994       Impact factor: 9.937

Review 9.  Correlates of protective immunity for Ebola vaccines: implications for regulatory approval by the animal rule.

Authors:  Nancy J Sullivan; Julie E Martin; Barney S Graham; Gary J Nabel
Journal:  Nat Rev Microbiol       Date:  2009-05       Impact factor: 60.633

10.  Ebola virus disease in West Africa--the first 9 months of the epidemic and forward projections.

Authors:  Bruce Aylward; Philippe Barboza; Luke Bawo; Eric Bertherat; Pepe Bilivogui; Isobel Blake; Rick Brennan; Sylvie Briand; Jethro Magwati Chakauya; Kennedy Chitala; Roland M Conteh; Anne Cori; Alice Croisier; Jean-Marie Dangou; Boubacar Diallo; Christl A Donnelly; Christopher Dye; Tim Eckmanns; Neil M Ferguson; Pierre Formenty; Caroline Fuhrer; Keiji Fukuda; Tini Garske; Alex Gasasira; Stephen Gbanyan; Peter Graaff; Emmanuel Heleze; Amara Jambai; Thibaut Jombart; Francis Kasolo; Albert Mbule Kadiobo; Sakoba Keita; Daniel Kertesz; Moussa Koné; Chris Lane; Jered Markoff; Moses Massaquoi; Harriet Mills; John Mike Mulba; Emmanuel Musa; Joel Myhre; Abdusalam Nasidi; Eric Nilles; Pierre Nouvellet; Deo Nshimirimana; Isabelle Nuttall; Tolbert Nyenswah; Olushayo Olu; Scott Pendergast; William Perea; Jonathan Polonsky; Steven Riley; Olivier Ronveaux; Keita Sakoba; Ravi Santhana Gopala Krishnan; Mikiko Senga; Faisal Shuaib; Maria D Van Kerkhove; Rui Vaz; Niluka Wijekoon Kannangarage; Zabulon Yoti
Journal:  N Engl J Med       Date:  2014-09-22       Impact factor: 91.245

View more
  38 in total

1.  Safety Precautions and Operating Procedures in an (A)BSL-4 Laboratory: 2. General Practices.

Authors:  Steven Mazur; Michael R Holbrook; Tracey Burdette; Nicole Joselyn; Jason Barr; Daniela Pusl; Laura Bollinger; Linda Coe; Peter B Jahrling; Matthew G Lackemeyer; Jiro Wada; Jens H Kuhn; Krisztina Janosko
Journal:  J Vis Exp       Date:  2016-10-03       Impact factor: 1.355

2.  The Integrity of the YxxL Motif of Ebola Virus VP24 Is Important for the Transport of Nucleocapsid-Like Structures and for the Regulation of Viral RNA Synthesis.

Authors:  Yuki Takamatsu; Larissa Kolesnikova; Martin Schauflinger; Takeshi Noda; Stephan Becker
Journal:  J Virol       Date:  2020-04-16       Impact factor: 5.103

3.  Ebolaviruses Associated with Differential Pathogenicity Induce Distinct Host Responses in Human Macrophages.

Authors:  Judith Olejnik; Adriana Forero; Laure R Deflubé; Adam J Hume; Whitney A Manhart; Andrew Nishida; Andrea Marzi; Michael G Katze; Hideki Ebihara; Angela L Rasmussen; Elke Mühlberger
Journal:  J Virol       Date:  2017-05-12       Impact factor: 5.103

4.  Polyamine Depletion Inhibits Bunyavirus Infection via Generation of Noninfectious Interfering Virions.

Authors:  Vincent Mastrodomenico; Jeremy J Esin; Marion L Graham; Patrick M Tate; Grant M Hawkins; Zachary J Sandler; David J Rademacher; Thomas M Kicmal; Courtney N Dial; Bryan C Mounce
Journal:  J Virol       Date:  2019-06-28       Impact factor: 5.103

5.  Axonal Transport Enables Neuron-to-Neuron Propagation of Human Coronavirus OC43.

Authors:  Mathieu Dubé; Alain Le Coupanec; Alan H M Wong; James M Rini; Marc Desforges; Pierre J Talbot
Journal:  J Virol       Date:  2018-08-16       Impact factor: 5.103

6.  The RNA-Binding Protein of a Double-Stranded RNA Virus Acts like a Scaffold Protein.

Authors:  Carlos P Mata; Johann Mertens; Juan Fontana; Daniel Luque; Carolina Allende-Ballestero; David Reguera; Benes L Trus; Alasdair C Steven; José L Carrascosa; José R Castón
Journal:  J Virol       Date:  2018-09-12       Impact factor: 5.103

7.  Ebola Virus Shedding and Transmission: Review of Current Evidence.

Authors:  Pauline Vetter; William A Fischer; Manuel Schibler; Michael Jacobs; Daniel G Bausch; Laurent Kaiser
Journal:  J Infect Dis       Date:  2016-07-20       Impact factor: 5.226

8.  Pathogenicity Comparison Between the Kikwit and Makona Ebola Virus Variants in Rhesus Macaques.

Authors:  Gary Wong; Xiangguo Qiu; Marc-Antoine de La Vega; Lisa Fernando; Haiyan Wei; Alexander Bello; Hugues Fausther-Bovendo; Jonathan Audet; Andrea Kroeker; Robert Kozak; Kaylie Tran; Shihua He; Kevin Tierney; Geoff Soule; Estella Moffat; Stephan Günther; George F Gao; Jim Strong; Carissa Embury-Hyatt; Gary Kobinger
Journal:  J Infect Dis       Date:  2016-09-19       Impact factor: 5.226

9.  Frontline Science: CD40 signaling restricts RNA virus replication in Mϕs, leading to rapid innate immune control of acute virus infection.

Authors:  Kai J Rogers; Olena Shtanko; Laura L Stunz; Laura N Mallinger; Tina Arkee; Megan E Schmidt; Dana Bohan; Bethany Brunton; Judith M White; Steve M Varga; Noah S Butler; Gail A Bishop; Wendy Maury
Journal:  J Leukoc Biol       Date:  2020-05-22       Impact factor: 4.962

Review 10.  Ebola virus disease.

Authors:  Shevin T Jacob; Ian Crozier; William A Fischer; Angela Hewlett; Colleen S Kraft; Marc-Antoine de La Vega; Moses J Soka; Victoria Wahl; Anthony Griffiths; Laura Bollinger; Jens H Kuhn
Journal:  Nat Rev Dis Primers       Date:  2020-02-20       Impact factor: 52.329

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.